UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
Recruiting now
Conditions studied: Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
In brief
This is an ambispective, observational, multicenter and multicohort study, targeting patients with NSCLC initiating approved drugs developed by AZ or as part of an AZ alliance, in the participating countries, as monotherapy or in combination at any stage of disease. Three cohorts are designed, based on the stage of NSCLC (resectable, unresectable and metastatic). The multicohort study is modular in design. Specific modules will be set up separately to assess each new indication of drugs developed by AZ or as part of an AZ alliance once European marketing authorization (MA) has been granted and made available in the participating countries. Patients will be enrolled in the study if they have received (retrospective), receive (retrospective and prospective) or will receive (prospective) approved drugs developed by AZ or as part of an AZ alliance according to the eligibility criteria. Treatment plan and decision are made independently by each treating physician prior to inclusion in this study.
Key facts
- Study ID
- NCT06726720
- Run by
- AstraZeneca
- People needed
- 300
- Starts
- 2024-12-16
- Expected to finish
- 2032-06-30
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients (≥ 18 years old)
- Patients with histologically or cytologically proven NSCLC
- Patients initiated with approved drugs developed by AZ or as part of an AZ alliance at the time of the enrollment or within the previous three weeks.
- Informed patients who consent to participate in the study as per local regulations.
You may not qualify if…
- Patients participating in an interventional clinical trial for NSCLC*
- with the exception on low-interventional studies (RIPH2) where the intervention does not involve the NSCLC treatment
- Patients already enrolled in another module of the cohort in UMBREALUNG
- Patients under safeguard of justice, curatorship or guardianship
Where it is running
- Research Site — Marseille, France (enrolling)
- Research Site — Marseille, France (enrolling)
- Research Site — Auxerre, France (enrolling)
- Research Site — Angers, France (enrolling)
- Research Site — Aurillac, France (enrolling)
- Research Site — Aix-en-Provence, France (enrolling)
- Research Site — Blois, France (enrolling)
- Research Site — Bordeaux, France (enrolling)
- Research Site — Bourg-en-Bresse, France (enrolling)
- Research Site — Avignon, France (enrolling)
- Research Site — Carcassonne, France (enrolling)
- Research Site — Chalon Sur Sa Ne, France (enrolling)
- Research Site — Chambéry, France (enrolling)
- Research Site — Châteauroux, France (enrolling)
- Research Site — Créteil, France (enrolling)
- Research Site — Dieppe, France (enrolling)
- Research Site — Dinan, France (enrolling)
- Research Site — Dreux, France (enrolling)
- Research Site — Epagny METZ Tessy, France (enrolling)
- Research Site — Fort de France Cedex, France (enrolling)
- Research Site — Le Coudray, France (enrolling)
- Research Site — Limoges, France (enrolling)
- Research Site — Lyon, France (enrolling)
- Research Site — Marseille, France (enrolling)
- Research Site — Meaux, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.